Detection of the Hanganutziu-Deicher antigen in patients with hepatocellular carcinoma

Koda, Toru; T, Shimosakoda; Asaoka, Hideyuki; Nishinaka, Shigeyuki; Tamura, Ikuo; Nakaba, Hiroyuki; Matsuda, Haruo

doi:10.1016/0928-4346(94)90025-6

Cited by 6 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, it has been reported that anti-NeuGc-containing ganglioside antibodies recognize some human tumours and cancerous cell lines [8,9]. These studies have been carried out using polyclonal or monoclonal antibodies from chicken [10], human [11], or murine origin [12], but in all these tumours minimal levels of NeuGc were reported. On the other hand, we found recently increased levels of GM3(NeuGc) ganglioside in human breast tumors [13], a finding that certainly makes this molecule an attractive target for cancer therapy.…”

Section: Introductionmentioning

confidence: 81%

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

Oliva

Valdés

Casacó

et al. 2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

The relevance of certain gangliosides in tumour growth and metastatic dissemination has been well documented, reasons for considering these molecules as potential targets for cancer immunotherapy and diagnosis. GM3(NeuGc) ganglioside is particularly interesting due to its restrictive expression in normal human tissues according to immunohistochemical studies, using either polyclonal or monoclonal antibodies. But both immunohistochemical and biochemical methods have strongly suggested its over-expression in human breast tumours. Nevertheless, the lack of a direct evidence of this antigenic display in human breast cancer has kept the subject controversial. For the first time, we described herein the "in vivo" detection of GM3(NeuGc) ganglioside in human breast primary tumours using a radioimmunoscintigraphic technique with 14F7, a highly specific anti-GM3(NeuGc) ganglioside monoclonal antibody, labelled with (99m)Tc. In an open, prospective Phase I/II clinical trial, including women diagnosed in stage II breast cancer, the 14F7 monoclonal antibody accumulation in tumours at doses of 0.3 (n=5), 1 (n=5) and 3 mg (n=4) was evaluated. Noteworthy, the immunoscintigraphic study showed antibody accumulation in 100% of patients' tumours for the 1 mg dose group. In turn, the radioimmunoconjugate injected at doses of 0.3 mg or 3 mg of the antibody, was uptaken by 60 and 33.3% of breast tumours, respectively. "In vivo" immune recognition of GM3(NeuGc) in breast tumours reinforces the value of this peculiar target for cancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 81%

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

Oliva

Valdés

Casacó

et al. 2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Some articles have described Nglycolylated neuraminic acid in hum an tumors stained with a murine monoclonal antibody (20) or chicken polyclonal antibodies. (10) Additionally, there are som e reports where NeuGccontaining ganglioside composition has been determined by biochemical analysis in human tumors (31,32) and cell lines. (8) We used a preliminary immunohistoch emical study with 14F7 in normal and tumor sections to clarify if human tumors express NeuGc antigen or not.…”

Section: Discussionmentioning

confidence: 99%

“…(6,7) In contrast, it has been reported that Anti-NeuGc-containing ganglioside antibodies (8,9) recognize some hum an tumors and cancerous cell lines. These studies have been carried out using polyclonal or monoclonal antibodies of chicken, (10) hum an, (11) or murine (12 ) origin, but in all these tumors minimal levels of NeuGc were reported. On the other hand, recently, we found increased levels of GM3(NeuGc) ganglioside in human breast cancer, (1 3) a finding that certainly makes this molecule an attractive target for cancer therapy.…”

Section: Introductionmentioning

confidence: 96%

A Mouse IgG₁Monoclonal Antibody Specific forN-Glycolyl GM3 Ganglioside Recognized Breast and Melanoma Tumors

et al. 2000

View full text Add to dashboard Cite

14F7 murine monoclonal antibody (MAb) is an IgG1 immunoglobulin that is generated by immunizing Balb/c mice with GM3(NeuGc) ganglioside hydrophobically conjugated with human very-low-density lipoproteins and in the presence of Freund's adjuvants. 14F7 MAb binds specifically to GM3(NeuGc), whereas neither N-glycolyl or N-acetyl gangliosides, nor a sulfated glycolipid, are recognized as assessed by enzyme-linked immunosorbent assay or immunostaining on thin layer chromatograms. Immunohistochemical studies in fresh tumor tissues showed that 14F7 MAb strongly recognized in antigen expressed in human breast and melanoma tumors.

show abstract

“…2,16 In our study, increased serum levels of IgG and /or IgM antibodies were observed in 13 of the 17 patients (76.5%), with the presence of these antibodies being attributed to the expression of NeuGc by HCC. Thus, there was a disparity between the detection of We found four patients (cases 3, 4, 5, and 8) in whom the tissue specimens were negative for NeuGc, but in whom serum anti-NeuGc antibodies were detected.…”

Section: Discussionmentioning

confidence: 72%

“…In our previous study, NeuGc was detected on tumor cells from patients with HCC by flow cytometric analysis, using two chicken monoclonal antibodies raised against NeuGc (Hu/Ch 2-7 and Hu/Ch 6-1). 2 However, there is still controversy concerning the role of NeuGc in human carcinogenesis, and no firm conclusions have been reached. One reason may be that almost all previous research has simply used anti-NeuGc antibodies to identify NeuGc expression.…”

Section: Discussionmentioning

confidence: 99%

Application of tyramide signal amplification for detection of N-glycolylneuraminic acid in human hepatocellular carcinoma

Koda

Aosasa

Asaoka

et al. 2003

International Journal of Clinical Oncology

View full text Add to dashboard Cite

The tyramide signal amplification method is useful for the immunohistochemical detection of low-level NeuGc expression by hepatocellular carcinoma cells. We therefore consider that measurement of serum levels of anti-NeuGc antibodies is clinically meaningful and that anti-NeuGc antibody may be a useful screening test, in combination with AFP and PIVKA-II, for the early diagnosis of hepatocellular carcinoma.

show abstract

Detection of the Hanganutziu-Deicher antigen in patients with hepatocellular carcinoma

Cited by 6 publications

References 4 publications

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

A Mouse IgG₁Monoclonal Antibody Specific forN-Glycolyl GM3 Ganglioside Recognized Breast and Melanoma Tumors

Application of tyramide signal amplification for detection of N-glycolylneuraminic acid in human hepatocellular carcinoma

Contact Info

Product

Resources

About

Detection of the Hanganutziu-Deicher antigen in patients with hepatocellular carcinoma

Cited by 6 publications

References 4 publications

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

A Mouse IgG1Monoclonal Antibody Specific forN-Glycolyl GM3 Ganglioside Recognized Breast and Melanoma Tumors

Application of tyramide signal amplification for detection of N-glycolylneuraminic acid in human hepatocellular carcinoma

Contact Info

Product

Resources

About

A Mouse IgG₁Monoclonal Antibody Specific forN-Glycolyl GM3 Ganglioside Recognized Breast and Melanoma Tumors